Robert A Olie Selected Research

Therapeutics

10/2018	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
1/2017	Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
1/2012	Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
3/2002	Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert A Olie Research Topics

Disease

4	Multiple Myeloma 01/2019 - 01/2012
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2019 - 01/2012
2	Neoplasms (Cancer) 06/2002 - 03/2002
1	Diarrhea 10/2018
1	Thrombocytopenia (Thrombopenia) 10/2018
1	Bone Diseases (Bone Disease) 01/2017
1	Vomiting 01/2017
1	Nausea 01/2017
1	Drug-Related Side Effects and Adverse Reactions 01/2012
1	Lung Neoplasms (Lung Cancer) 06/2002
1	Melanoma (Melanoma, Malignant) 03/2002

Drug/Important Bio-Agent (IBA)

4	Bortezomib (Velcade)FDA Link 01/2019 - 01/2012
2	oligonucleotide 4625IBA 06/2002 - 03/2002
2	OligonucleotidesIBA 06/2002 - 03/2002
2	Messenger RNA (mRNA)IBA 06/2002 - 03/2002
1	Antisense OligonucleotidesIBA 03/2002
1	Proteins (Proteins, Gene)FDA Link 03/2002

Therapy/Procedure

4	Therapeutics 10/2018 - 03/2002
2	Retreatment 01/2019 - 01/2012
1	Stem Cell Transplantation 01/2017